Endo Pharmaceuticals Holdings (ENDP) Tops Q3 EPS by 6c, Reaffirms Guidance
Get Alerts ENDP Hot Sheet
Price: $0.29 --0%
Financial Fact:
Selling, general and administrative: 159.9M
Today's EPS Names:
SHIM, KOD, HEWA, More
Financial Fact:
Selling, general and administrative: 159.9M
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q3 EPS of $1.25, $0.06 better than the analyst estimate of $1.19. Revenue for the quarter came in at $759 million versus the consensus estimate of $750.26 million.
Company reaffirms 2011 guidance for revenue of $2.72 to $2.80 billion and adjusted diluted EPS of $4.55 to $4.65; now expects reported or GAAP diluted EPS of $1.87 to $1.97.
Company reaffirms 2011 guidance for revenue of $2.72 to $2.80 billion and adjusted diluted EPS of $4.55 to $4.65; now expects reported or GAAP diluted EPS of $1.87 to $1.97.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Surf Air Mobility Inc. (SRFM) Reports revenue, provides guidance
- Verint Systems (VRNT) Tops Q4 EPS by 10c, Offers Guidance
- Sprinklr (CXM) Tops Q4 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!